SpiraCheck Ltd Analysis: $1M Raised
What is SpiraCheck Ltd?
Multi-cancer breath test for early detection
Location
London, United Kingdom
Employees
1-10
Founded
2016
Product Features & Capabilities
- Breath-based multi-cancer early detection test identifying VOCs
- Algorithm developed by Professor George Hanna's team at Imperial College London
- Clinical validation across 16 cancer types including oesophageal, gastric, pancreatic, and colorectal
- Patented biomarker discovery methods
- Non-invasive screening for patients at high risk of GI cancers
Use Cases
Screen high-risk patients for gastrointestinal cancers using a single breath test; Rule out GI cancers in patients with symptoms; Reduce invasive diagnostic procedures through better prioritisation; Monitor treatment effectiveness by tracking disease progression; Enable early detection in under-50s with rising bowel cancer rates; Support UK's less survivable cancers taskforce goals for improved survival rates
Other Considerations
Six completed clinical biomarker trials (n=2,352; 580 with cancer); Ten ongoing grant-funded clinical trials (>30,000 patients); Developed by Professor George Hanna's team at Imperial College London; Backed by patents licensed to SpiraCheck; Recognized in UK 'Less Survivable Cancers Taskforce' reports; Attended Emerging Medtech Summit 2024
See something that needs updating? Suggest edits to this profile.